Fibrosis in Patients with Chronic Hepatitis C: Detection and Significance

ABSTRACT

Estimates of the extent of hepatic fibrosis and the rate of fibrosis progression represent important surrogate end points for evaluation of the vulnerability of an individual patient and for assessment of the impact of treatment on natural history in chronic hepatitis C. Using the median fibrosis progression rate, the median expected time to cirrhosis in untreated patients is around 30 years. However, one third of patients have an expected median time to cirrhosis of less than 20 years and one third will only progress to cirrhosis in more than 50 years, if ever. Factors independently associated with fibrosis progression are duration of infection, age, male gender, consumption of alcohol, human immunodeficiency virus co-infection, and low CD4 count. Evaluation of fibrosis progression is useful to decide treatment. Among patients with sustained viral response, fibrosis regresses. Evaluation of fibrosis progression has permitted validation of the concept of suppressive therapy. Among patients without viral clearance, interferon alone or in combination with ribavirin significantly reduces fibrosis progression rate in comparison with progression before treatment and to control groups. There is a major need for noninvasive markers of liver fibrosis. None are clearly useful today for the diagnosis of early stages of fibrosis.

KEYWORD

fibrosis - HCV - ribavirin - liver biopsy

REFERENCES

• 1 WHO. Hepatitis C: global prevalence.  Wkly Epidemiol Rec . 1997;  72 341-344
• 2 Seeff L B, Buskell-Bales Z, Wright E C. Long-term mortality after transfusion-associated non-A non-B hepatitis.  N Engl J Med . 1992;  327 1906-1911
• 3 Tong M J, el-Farra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C.  N Engl J Med . 1995;  332 1463-1466
• 4 Darby S C, Ewart D W, Giangrande P LF. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C.  Lancet . 1997;  350 1425-1431
• 5 El-Serag H B, Mason A. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med . 1999;  34 745-750
• 6 Taylor-Robinson S D, Foster G R, Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94 [letter].  Lancet . 1997;  350 1142-1143
• 7 Deuffic S, Poynard T, Buffat L, Valleron A-J. Trends in primary liver cancer [letter].  Lancet . 1998;  351 214-215
• 8 Deuffic S, Buffat L, Poynard T, Valleron A J. Modeling the hepatitis C virus epidemic in France.  Hepatology . 1999;  29 1596-1601
• 9 Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C.  Lancet . 1997;  349 825-832
• 10 Sobesky R, Mathurin P, Charlotte F. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view.  Gastroenterology . 1999;  116 378-386
• 11 Perrillo R P. The role of liver biopsy in hepatitis C.  Hepatology . 1997;  26 57S-61S
• 12 Consensus Statement. EASL International Consensus Conference on Hepatitis C.  J Hepatol . 1999;  30 956-961
• 13 Poynard T, Lebrec D. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions.  Liver . 1982;  2 369-375
• 13a Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment.  J Hepatol . 1991;  13 372-374
• 14 Ludwig J. The nomenclature of chronic active hepatitis: an obituary.  Gastroenterology . 1993;  105 274-278
• 15 Desmet V J, Gerber M, Hoofnagle J H, Manns M, Scheuer P J. Classification of chronic hepatitis: diagnosis, grading and staging.  Hepatology . 1994;  19 1513-1519
• 16 Bedossa P, Poynard T, the METAVIR Cooperative Group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C.  Hepatology . 1994;  20 1:15-20
• 17 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.  Hepatology . 1996;  24 289-293
• 18 Knodell K G, Ishak K G, Black W C. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.  Hepatology . 1981;  1 431-435
• 19 Wong V S, Wight D G, Palmer C R, Alexander G J. Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model.  J Clin Pathol . 1996;  49 465-469
• 20 Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups.  J Viral Hepatol . 1997;  4 199-208
• 21 Paradis V, Mathurin P, Laurent A. Histological features predictive of liver fibrosis in chronic hepatitis C infection.  J Clin Pathol . 1996;  49 998-1004
• 22 Yano M, Kumada H, Kage M. The long term pathological evolution of chronic hepatitis C.  Hepatology . 1996;  23 1334-1340
• 23 Datz C, Cramp M, Haas T. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre.  Gut . 1999;  44 563-567
• 24 Poynard T, McHutchison J, Davis G, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J, and the FIBROVIRC Project Group. Impact of interferon alfa-2b and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C.  Hepatology . 1998;  28 497A
• 25 Wiley T E, McCarthy M, Breidi L, McCarthy M, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection.  Hepatology . 1998;  28 805-809
• 26 Benhamou Y, Bochet M, Di Martino V. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.  Hepatology . 1999;  30 1054-1058
• 27 von Frerichs. Uber den diabetes Berlin: Hirschwald 1884
• 28 Schupfer F. De la possibilité de faire ``intra vitam'' un diagnostic précis des maladies du foie et de la rate.  Semin Méd . 1907;  27 229-230
• 29 Huard P. La ponction biopsie du foie et son utilité dans le diagnostic des affections hépatiques.  Ann Anat Path . 1935;  12 1118-1124
• 30 Theodossi A, Spiegelhalter D, Portmann B, Eddleston A L, Williams R. The value of clinical, biochemical, ultrasound and liver biopsy data in assessing patients with liver disease.  Liver . 1983;  3 315-326
• 31 Soloway R D, Baggenstoss A H, Schoenfield L J, Summerskill W H. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy.  Am J Dig Dis . 1971;  16 1082-1086
• 32 Theodossi A, Skene A M, Portmann B. Observer variation in assessment of liver biopsies including analysis by kappa statistics.  Gastroenterology . 1980;  79 232-241
• 33 Pagliaro L, Rinaldi F, Craxi A. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial.  Dig Dis Sci . 1983;  28 39-43
• 34 Colombo M, Del Ninno E, de Franchis R. Ultrasound-assisted percutaneous liver biopsy: superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis.  Gastroenterology . 1998;  95 487-489
• 35 Papini E, Pacella C M, Rossi Z. A randomized trial of ultrasound-guided anterior subcostal liver biopsy versus the conventional Menghini technique.  J Hepatol . 1991;  13 291-297
• 36 Lindor K D, Bru C, Jorgensen R A. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy.  Hepatology . 1996;  23 1079-1083
• 37 Maharaj B, Maharaj R J, Leary W P. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver.  Lancet . 1986;  1 523-525
• 38 Crawford A R, Lin X Z, Crawford J M. The normal adult human liver biopsy: a quantitative reference standard.  Hepatology . 1998;  28 323-331
• 39 Urena M A, Ruiz-Delgado F C, Gonzalez E M. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program.  Transplant Proc . 1998;  30 3288-3291
• 40 Gayral F, Potier M, Salmon R, Labayle D, Larrieu H. Vascular complications of needle biopsy of the liver.  J Chir (Paris) . 1979;  116 261-264
• 41 Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou J P. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure.  Gastroenterology . 1982;  83 338-340
• 42 Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies.  J Hepatol . 1986;  2 165-173
• 43 McGill D B, Rakela J, Zinsmeister A R, Ott B J. A 21-year experience with major hemorrhage after percutaneous liver biopsy.  Gastroenterology . 1990;  99 1396-1400
• 44 Maharaj B, Bhoora I G. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken.  Postgrad Med J . 1992;  68 964-967
• 45 Van Thiel H D, Gavaler J S, Wright H, Tzakis A. Liver biopsy. Its safety and complications as seen at a liver transplant center.  Transplantation . 1993;  55 1087-1090
• 46 Janes C H, Lindor K D. Outcome of patients hospitalized for complications after outpatient liver biopsy.  Ann Intern Med . 1993;  118 96-98
• 47 Gilmore I T, Burroughs A, Murray-Lyon I M, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London.  Gut . 1995;  36 437-441
• 48 Vivas S, Palacio M A, Rodriguez M, Lomo J, Cadenas F, Giganto F, Rodrigo L. Ambulatory liver biopsy: complications and evolution in 264 cases.  Rev Esp Enferm Dig . 1998;  90 175-182
• 49 Teare J P, Sherman D, Greenfield S M. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis.  Lancet . 1993;  342 895-898
• 50 Oberti F, Valsesia E, Pilette C. Noninvasive diagnosis of hepatic fibrosis or cirrhosis.  Gastroenterology . 1997;  113 1609-1616
• 51 Bonacini M, Hadi G, Govindarajan S, Lindsay K L. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.  Am J Gastroenterol . 1997;  92 1302-1304
• 52 Gaiani S, Gramantieri L, Venturoli N. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis?.  <~>A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol . 1997;  27 979-985
• 53 Aube C, Oberti F, Korali N. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis.  J Hepatol . 1999;  30 472-478
• 54 Mathurin P, Moussalli J, Cadranel J F. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.  Hepatology . 1998;  27 868-872
• 55 Shiffman M L, Hofmann C M, Contos M J, Luketic V A, Sanyal A J, Sterling R K, Ferreira-Gonzalez A, Mills A S, Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.  Gastroenterology . 1999;  117 1164-1172
• 56 Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effects of dose and duration.  Hepatology . 1996;  24 778-789
• 57 Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis.  J Hepatol . 1997;  26 1187-1199
• 58 Capra F, Casaril M, Gabrielli G B. Dolci Alpha-interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.  J Hepatol . 1993;  18 112-118
• 59 Fukuda Y, Nakano I, Katano Y. Assessment and treatment of liver disease in Japanese haemophilia patients.  Haemophilia . 1998;  4 595-600
• 60 Kaplanski G, Farnarier C, Payan M J, Bongrand P, Durand J M. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis.  Dig Dis Sci . 1997;  42 2277-2284
• 61 Kasahara A, Hayashi N, Mochizuki K. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.  J Hepatol . 1997;  26 574-583
• 62 Mazzoran L, Tamaro G, Mangiarotti M A. Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease.  Eur J Gastroenterol Hepatol . 1998;  10 125-131
• 63 Napoli J, Bishop G A, McGuinness P H, Painter D M, McCaughan G W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines.  Hepatology . 1996;  24 759-765
• 64 Verbaan H, Bondeson L, Eriksson S. Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection.  Scand J Gastroenterol . 1997;  32 494-499
• 65 Wong V S, Hughes V, Trull A, Wight D G, Petrik J, Alexander G J. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection.  J Viral Hepatol . 1998;  5 187-192
• 66 Yamada M, Fukuda Y, Koyama Y. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.  J Gastroenterol Hepatol . 1996;  11 646-651
• 67 Yamada M, Fukuda Y, Nakano I, Katano Y, Takamatsu J, Hayakawa T. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease.  Acta Haematol . 1998;  99 212-216